Business
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET. A live webcast of the call a
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"image","alt":"Arcutis Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Arcutis Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NsgskJmcmYR2weZA9OX0jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3","width":300,"height":54}},"lazy":false},{"type":"text","content":"WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET.","length":476,"tagName":"p"},{"type":"text","content":"A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the conference call.","length":234,"tagName":"p"},{"type":"text","content":"About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.","length":826,"tagName":"p"},{"type":"text","content":"Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securitie...